DIAGNOSIS AND TREATMENT OF METACHRONOUS TESTICULAR CANCER: A CLINICAL CASE

The incidence of bilateral testicular cancer is 5% in the total cohort of patients. Synchronous and metachronous testicular cancers are detected in 1-2 and 3% of cases, respectively. The standard treatment for testicular cancer is orchifuniculectomy and that for synchronous or metachronous cancer is organ-saving treatment, testectomy.

The paper describes a clinical case of multiple primary metachronous testicular cancer. A 24-year-old patient underwent surgery (orchifuniculectomy) and received 4 courses of BEP polychemotherapy for embryonal carcinoma of the left testicle at the P.A. Herzen Moscow Oncology Research Institute. After 55 months, a dynamic control examination diagnosed a 9-mm tumor in his single right testis that was thereafter resected. Its histological examination revealed embryonal carcinoma with solitary structures in the immature teratoma. Following 22 months, a control examination showed a recurrence of the disease, for which orchifuniculectomy of the single right testis, followed by hormone replacement therapy, was performed. The follow-up period was 80 months; no recurrence is now observed.

1. Заридзе Д.Г. Профилактика рака, руководство для врачей. М.: ИМА-пресс, 2009.

2. Чиссов В.И., Дарьялова С.Л. Клинические рекомендации. Онкология. М.: ГЭО-ТАР-Медиа, 2006.

3. Злокачественные новообразования в России в 2010 году (заболеваемость и смертность). Под ред. В.И. Чиссова, В.В.Старинского. М., 2012.

4. Dijkstra S.S., Witjes J.A. A patient with bilateral testicular cancer. Ned Tijdschr Geneeskd 2012;156(11):A3392.

5. McGlynn K.A., Devesa S.S., Sigurdso n A.J. et al. Trends in the incidence of testicular germ cell tumours in the United States. Cancer 2003;97(1):63–70. http://www.ncbi.nlm.nih.gov/pubmed/12491506

6. Che M., Tamboli P., Ro J.Y. et al. Bilateral testicular germ cell tumors: twenty-year experience at M. D. Anderson Cancer Center. Department of Pathology, The University of Texas M. D. Anderson Cancer Center, Houston 77030, USA 2002 Sep 15;95(6):1228–33.

7. Moller H., Prener A., Skakkebaek N.E. Testicular cancer, cryptorchidism, inguinal hernia, testicular atrophy and genital malformations: case-control studies in Denmark. Cancer Causes Control 1996;7(2):264–74. http://www.ncbi.nlm.nih.gov/pubmed/8740739

8. Weestergaard T., Olsen J.H., Frisch M. et al. Cancer risk in fathers and brothers of testicular cancer patients in Denmark. A population based study. Int J Cancer 1996;66(5):627–31. http://www.ncbi.nlm.nih.gov/pubmed/8647624

9. Géczi L., Gomez F., Bak M., Bodrogi I. The incidence, prognosis, clinical and histological characteristics, treatment, and outcome of patients with bilateral germ cell testicular cancer in Hungary. 2003 May;129(5):309–15. Epub 2003 May 14.

10. Weissbach L. Organ Preserving Surgery of Malignant Germ Cell Tumors. J Urol 1995;153:90–3.

11. Heidenreich A., Bonfig R., Derschum W. et al. A conservative approach to bilateral testicular germ cell tumors. J Urol 1995;153:10–3.

12. Dieckmann K.P., Kulejewski M., Pichlmeier U., Loy V. Albertinen-Krankenhaus Hamburg, Urologische Abteilung, Germany. Diagnosis of contralateral testicular intraepithelial neoplasia (TIN) in patients with testicular germ cell cancer: systematic two-site biopsies are more sensitive than a single random biopsy. 2007 Jan;51(1):175–83; discussion 183–5. Epub 2006 Jun 13.

13. Dieckmann K.P., Classen J., Souchon R., Loy V. Management of testicular intraepithelial neoplasia (TIN) – a review based on the principles of evidence-based medicine. 2001 Jan 15;113(1–2):7–14.

14. Heidenreich A., Moul J.W. Department of Urology and Pediatric Urology, Phillips University, Marburg, Germany. Contralateral testicular biopsy procedure in patients with unilateral testis cancer: is it indicated? Urol Ann 2011;3(3):115–8.

15. Heidenreich A., Weissbach L., Höltl W. et al. German Testicular Cancer Study Group. Department of Urology, Philipps-University Marburg, Marburg, Krankenhaus Am Urban, Berlin, Germany.Organ sparing surgery for malignant germ cell tumor of the testis. 2001 Dec;166(6):2161–5.

16. Von der Maase H., Giwercman A., Skakkebaek N.E. Radiation treatment of carcinoma-in-situ of testis. Lancet 1986;1:624–5.

17. Fizazi K., Oldenburg J., Dunant A. et al. Assessing prognosis and optimizing treatment in patients with postchemotherapy viable nonseminomatous germ-cell tumors (NSGCT): results of the sCR2 international study. Ann Oncol 2008;19(2):259–64. http://www.ncbi.nlm.nih.gov/pubmed/18042838

18. Hendry W.F., Norman A., Nicholls J. et al. Abdominal relapse in stage 1 nonseminomatous germ cell tumours of the testis managed by surveillance or with adjuvant chemotherapy. BJU Int 2000;86(1):89–93. http://www.ncbi.n lm.nih.gov/pubmed/10886090

19. Dieckmann K.P., Loy V., Buttner P. Prevalence of bilateral germ cell tumours and early detection based on contralateral testicular intraepithelial neoplasia. Br J Urol 1993;71(3):340–5. http://www.ncbi.nlm.nih.gov/pubmed/8386582

20. Tandstad T., Dahl O., Cohn-Cedermar k G. et al. Risk-adapted treatment in clinical stage 1 (CS1), nonseminomatous germ cell testicular cancer (NSGCT), the SWENOTECA management program. Heidenreich A. BJU Int 2009;104(9 Pt B):1346–50. Review.PMID: 19840011 [PubMed – indexed for MEDLINE].